Author:
Lüftner Diana,Banys-Paluchowski Maggie,Ditsch Nina,Fasching Peter A.,Jackisch Christian,Janni Wolfgang,Krug David,Untch Michael,Harbeck Nadia,Huober Jens
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. AGO Kommission Mamma Diagnostik und Therapie früher und fortgeschrittener Mammakarzinome (März 2023). https://www.ago-online.de/fileadmin/ago-online/downloads/_leitlinien/kommission_mamma/2023/AGO_2023D_Gesamtdatei.pdf. Zugegriffen: 3. Apr. 2023
2. Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816
3. Díaz-Roldán J, Eguía-Larrea M, Rubio-Sánchez T et al (2022) Systematic review of synchronous contralateral axillary metastases in breast cancer: really M1 disease? Breast Cancer 29(1):9–18
4. Domchek SM, Postel-Vinay S, Im S‑A et al (2020) Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol 21(9):1155–1164
5. Francis PA, Regan MM, Fleming GF et al (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372(5):436–446